Categories: News

Wave Life Sciences to Webcast Conference Call of Second Quarter 2022 Financial Results on August 11, 2022

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast and conference call at 8:30 a.m. ET on Thursday, August 11, 2022, to discuss the company’s second quarter 2022 financial results and provide a business update.

The webcast of the conference call may be accessed by visiting “Events” at the investor relations section of the Wave Life Sciences corporate website: ir.wavelifesciences.com/events-and-presentations.

Analysts planning to participate during the Q&A portion of the live call can join the conference call at the following audio conferencing link: available here. It is recommended that participants register at least 15 minutes in advance of the call. Once registered, participants will receive the dial-in information.

Following the live event, an archived version of the webcast will be available on the Wave Life Sciences website.

About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company’s proprietary discovery and drug development platform that enables the precise design, optimization, and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future. To find out more, please visit www.wavelifesciences.com and follow Wave on Twitter @WaveLifeSci.

Investor Contact:
Kate Rausch
617-949-4827
krausch@wavelifesci.com

Media Contact:
Alicia Suter
617-949-4817
asuter@wavelifesci.com

Staff

Recent Posts

Financière de Tubize – 2025 half-year financial report

Half-year financial report 2025Regulated information 2 August 2025 The board of directors of Financière de…

18 hours ago

KORU Medical Systems Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading…

1 day ago

NIIMBL Announces Project Call 9.1 – New Funding Available for Biopharma Innovation

NEWARK, Del., Aug. 1, 2025 /PRNewswire/ -- The National Institute for Innovation in Manufacturing Biopharmaceuticals…

1 day ago

MiRus Receives New Technology Add-on Payment (NTAP) for EUROPA™ Posterior Cervical Fusion System

ATLANTA, Aug. 1, 2025 /PRNewswire/ -- MiRus has received New Technology Add-on Payment (NTAP) from…

1 day ago

BillionToOne Expands Executive Team to Support Growth of UNITY and Northstar Platforms

New Leaders Bring Deep Expertise in Operational Efficiency MENLO PARK, Calif., Aug. 1, 2025 /PRNewswire/…

1 day ago

Experity Appoints Bobby Ghoshal as President and Chief Operating Officer

CHICAGO, Aug. 1, 2025 /PRNewswire/ -- Experity, the national leader in on-demand healthcare solutions, today announced…

1 day ago